Trifluridine/tipiracil : A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia
© 2020 John Wiley & Sons Australia, Ltd..
Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents. This article reviews trifluridine/tipiracil clinical data and presents practical information on its use in the management of refractory mCRC in Australia. Whereas the primary mechanism of action of fluoropyrimidines such as fluorouracil (5-FU) and capecitabine is enzyme inhibition of nucleotide synthesis, trifluridine/tipiracil primarily acts by incorporation into DNA, resulting in DNA dysfunction. Trifluridine/tipiracil has activity in patients with 5-FU-resistant tumors and can be considered in patients with prior intolerance or toxicity to 5-FU. In the pivotal phase III RECOURSE trial evaluating trifluridine/tipiracil in chemotherapy-refractory mCRC, efficacy benefits were observed across all a priori prognostic subgroups including those defined by age (≥65 and ≥75 years), geographical origin, primary tumor site or KRAS status. Trifluridine/tipiracil therapy benefits appropriately selected patients who have an ECOG performance status of 0 or 1, with no more than mild hepatic impairment or mild-to-moderate renal impairment, and who are capable of adhering to oral therapy safely. Appropriate dosing, monitoring for adverse events and effective management of side effects are essential.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 Suppl 1 |
|---|---|
| Enthalten in: |
Asia-Pacific journal of clinical oncology - 16 Suppl 1(2020) vom: 02. Apr., Seite 3-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Price, Timothy [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.07.2020 Date Revised 10.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajco.13336 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309318750 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309318750 | ||
| 003 | DE-627 | ||
| 005 | 20231225133642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajco.13336 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309318750 | ||
| 035 | |a (NLM)32348018 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Price, Timothy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trifluridine/tipiracil |b A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2020 | ||
| 500 | |a Date Revised 10.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons Australia, Ltd. | ||
| 520 | |a Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents. This article reviews trifluridine/tipiracil clinical data and presents practical information on its use in the management of refractory mCRC in Australia. Whereas the primary mechanism of action of fluoropyrimidines such as fluorouracil (5-FU) and capecitabine is enzyme inhibition of nucleotide synthesis, trifluridine/tipiracil primarily acts by incorporation into DNA, resulting in DNA dysfunction. Trifluridine/tipiracil has activity in patients with 5-FU-resistant tumors and can be considered in patients with prior intolerance or toxicity to 5-FU. In the pivotal phase III RECOURSE trial evaluating trifluridine/tipiracil in chemotherapy-refractory mCRC, efficacy benefits were observed across all a priori prognostic subgroups including those defined by age (≥65 and ≥75 years), geographical origin, primary tumor site or KRAS status. Trifluridine/tipiracil therapy benefits appropriately selected patients who have an ECOG performance status of 0 or 1, with no more than mild hepatic impairment or mild-to-moderate renal impairment, and who are capable of adhering to oral therapy safely. Appropriate dosing, monitoring for adverse events and effective management of side effects are essential | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adverse effects | |
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a patient selection | |
| 650 | 4 | |a treatment efficacy | |
| 650 | 4 | |a trifluridine/tipiracil | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Pyrrolidines |2 NLM | |
| 650 | 7 | |a trifluridine tipiracil drug combination |2 NLM | |
| 650 | 7 | |a Uracil |2 NLM | |
| 650 | 7 | |a 56HH86ZVCT |2 NLM | |
| 650 | 7 | |a Thymine |2 NLM | |
| 650 | 7 | |a QR26YLT7LT |2 NLM | |
| 650 | 7 | |a Trifluridine |2 NLM | |
| 650 | 7 | |a RMW9V5RW38 |2 NLM | |
| 700 | 1 | |a Burge, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Chantrill, Lorraine |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbs, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlakis, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Sjoquist, Katrin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Asia-Pacific journal of clinical oncology |d 2010 |g 16 Suppl 1(2020) vom: 02. Apr., Seite 3-12 |w (DE-627)NLM197405231 |x 1743-7563 |7 nnns |
| 773 | 1 | 8 | |g volume:16 Suppl 1 |g year:2020 |g day:02 |g month:04 |g pages:3-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajco.13336 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 Suppl 1 |j 2020 |b 02 |c 04 |h 3-12 | ||